CJC-1295, Ipamorelin 10mg (Blend)

68.00 USD

Availability: In stock

FREE Shipping for orders over $200 (USA Only)

$15.00 Flat Rate Shipping Worldwide (Most Countries) 

*Includes one 30mL Bacteriostatic Water with orders over $300.00

$68.00
  • Buy 5 for $65.00 each and save 5%
  • Buy 10 for $60.00 each and save 12%
CJC-1295 5mg, Ipamorelin 5mg (10mg Total Blend)

CJC-1295, Ipamorelin 10mg (Blend)

Double click on above image to view full picture

Zoom Out
Zoom In
Product Usage: THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.

Ipamorelin is one of the most selective growth hormone (GH) secretagogues known and a potent agonist of the ghrelin/growth hormone secretagogue receptor[1]. It has been heavily researched in a number of settings and is known to, improve bone health, boost muscle repair and development, stimulate insulin release from the pancreas, and improve bowel motility and gastric function[2]–[6].

CJC-1295 also causes the release of GH, but it does so by stimulating the growth hormone releasing hormone receptor. It is also highly selective and has demonstrated positive benefits on bone health, lean body mass, insulin resistance, and muscle growth and development[7]–[9]. By combing the two peptides, it may be possible to produce enhanced effects because they stimulate the growth hormone axis via two different mechanisms. Research in animal models using both peptides is likely to show increased benefit without substantially increased side effects.

Ipamorelin is likely to raise baseline levels of GH such that CJC-1295 will be able to produce both higher peaks and higher troughs while preserving normal growth hormone pulsatile secretion. The net effect of combing the peptides would be a higher set point for the normal ebb and flow of GH, resulting in improved lean body mass, better muscle development, improved use of insulin, and overall better metabolic function.

About The Author

Research by L. Edmiston, M.D. for Peptide Sciences. L. Edmiston holds an M.D. from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Resources

  • [1] K. Raun et al., “Ipamorelin, the first selective growth hormone secretagogue,” Eur. J. Endocrinol., vol. 139, no. 5, pp. 552–561, Nov. 1998. [PubMed]
  • [2] N. B. Andersen, K. Malmlöf, P. B. Johansen, T. T. Andreassen, G. Ørtoft, and H. Oxlund, “The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats,” Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc., vol. 11, no. 5, pp. 266–272, Oct. 2001. [PubMed]
  • [3] J. Svensson et al., “The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats,” J. Endocrinol., vol. 165, no. 3, pp. 569–577, Jun. 2000. [PubMed]
  • [4] E. Adeghate and A. S. Ponery, “Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats,” Neuro Endocrinol. Lett., vol. 25, no. 6, pp. 403–406, Dec. 2004. [PubMed]
  • [5] D. E. Beck, W. B. Sweeney, M. D. McCarter, and Ipamorelin 201 Study Group, “Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients,” Int. J. Colorectal Dis., vol. 29, no. 12, pp. 1527–1534, Dec. 2014. [PubMed]
  • [6] B. Greenwood-Van Meerveld, K. Tyler, E. Mohammadi, and C. Pietra, “Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus,” J. Exp. Pharmacol., vol. 4, pp. 149–165, Oct. 2012. [PubMed]
  • [7] M. Alba et al., “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse,” Am. J. Physiol. Endocrinol. Metab., vol. 291, no. 6, pp. E1290-1294, Dec. 2006. [PubMed]
  • [8] M. Ionescu and L. A. Frohman, “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog,” J. Clin. Endocrinol. Metab., vol. 91, no. 12, pp. 4792–4797, Dec. 2006. [PubMed]
  • [9] M. C. Van Hout and E. Hearne, “Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions,” Subst. Use Misuse, vol. 51, no. 1, pp. 73–84, Jan. 2016. [PubMed]